echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The CD39 monoclonal antibody of Kewang Pharma is approved for clinical use in China

    The CD39 monoclonal antibody of Kewang Pharma is approved for clinical use in China

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    TextPharmaceutical Guanlan

    On February 8, Kewang Pharma announced that its innovative antibody drug ES002 clinical trial application has obtained the implied license from the Center for Drug Evaluation (CDE) of the State Drug Administration of China, and will soon start a Phase 1 clinical trial in China


    Published data show that CD39 is a key rate-limiting enzyme on the ATP-adenosine pathway and plays a crucial role in the immune regulation of the tumor microenvironment


    ES002 promotes antitumor immune responses by targeting CD39


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.